

Triazines for Malaria Treatment & Prophylaxis

Status

The Army seeks a partner interested in commercializing this technology.

*Title: Substituted
Triazines for Malaria
Treatment and
Chemoprophylaxis*

*Patent Applications:
PCT/US/2014/
025586 filed 13
March 2014*

*Inventors: , Richard J.
Sciotti, Victor E.
Zottig, Gregory A.
Reichard*

**Available
For
Licensing**

The Technology

This triazine class of molecules represents a novel class of anti-malarial drugs that structurally do not resemble current malaria treatments. This fact is important because, as with all infectious diseases, there is continuing development of resistance to current drug treatments based on the chemical structure of the drug agent. This particular chemical series also contains all the desirable features for an antimalarial agent: high potency, potential for weekly dosing, safe and inexpensive to produce.



Application

An approved triazine anti-malarial drug could be used for both malaria treatment and malaria chemoprophylaxis. In 2013 an estimated 198 million cases of malaria occurred worldwide and 500,000 people died, mostly children in the African Region. The Centers for Disease Control (CDC) estimates that approximately 1,500 travelers per year become infected with malaria abroad and then return to the US. In addition, Malaria is the number one infectious disease threat to our deployed US troops.

Benefits

- The invention includes a new class of anti-malarial compounds
- Animal data supports safety and efficacy
- Anticipated regimen is weekly dosing
- Cost to acquire the drug will be low
- If/when approved, can be used as prophylaxis or treatment
- Human clinical trials are planned

Contact

USAMRMC ORTA, 301-619-6975, USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil

